Biomarqueurs des carcinomes pulmonaires à petites cellules en 2022

Abstract

AbstractConversely of non-small cell lung cancer, the small cell lung cancer (SCLC) made little profit since last twenty years from discoveries of molecules based notably of genomic alteration, in order to develop new therapeutic targets. Recent data, based on the expression of dominant transcriptional signatures, then on methylome studies, permitted classification of SCLCs into four biologically distinct subtypes, namely, SCLC-A, SCLC-N, SCLC-P, and SCLC-I. This molecular characterization led to new classification of these cancers. The different subtypes can be identified on variable immunohistochemical profiles thanks to the use of anti-ASCL1, NEUROD1, POU2F3 and YAP1 antibodies. These histo-molecular subtypes are associated with a predictive potential for emerging and promising therapies, including PARP inhibitors, immune checkpoint inhibitors, and DLL3 therapies. In this context, an immunohistochemistry analysis combining the four antibodies cited above, plus anti-DLL3 and anti-SLFN11 antibodies might be soon necessary in clinical practice. The new findings offer a glimmer of hope for patients and open room for increasing the quality of life as well as the over all survival of SCLC patients in the near future.